Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax and Revumenib in AML MRD
NCT06284486Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of revumenib in acute myeloid leukemia (AML), sponsored by University of Texas MD Anderson Cancer Center. Started Sep 2024; status: recruiting.
02
Drugs
revumenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06284486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06284486.